Insulin assays and reference values

Diabetes and Metabolism

Volumn 25, Issue 6, 1999, Pages 459-476

  Chevenne, D ^a,b   Trivin, F ^b   Porquet, D ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b SAINT JOSEPH HOSPITAL   (France)

Author keywords

C peptide; Diabetes; Hypoglycaemia; Immunoradiometric assay; Insulin; Intravenous glucose tolerance test; Oral glucose tolerance test; Proinsulin; Radioimmunoassay

Indexed keywords

C PEPTIDE; INSULIN; MONOCLONAL ANTIBODY; PROINSULIN;

DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULINEMIA; INSULINOMA; INTRAVENOUS GLUCOSE TOLERANCE TEST; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PROTEIN DEGRADATION; REVIEW;

C-PEPTIDE; HUMANS; IMMUNOASSAY; INSULIN; ISLETS OF LANGERHANS; REFERENCE VALUES;

EID: 0033428863     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (204)

1. Yalow RS, Berson SA. Assay of plasma insulin in human subjects by immunological methods. Nature, 1959, 184, 1648-1649.
2. Orci L. The insulin factory: a tour of the plant surrounding and a visit to the assembly line. Diabetologia. 1985, 28, 528-546.
3. Bendayan M. Sécrétion d'insuline: parcours intracellulaire et cheminement extracellulaires. Médecine/Sciences, 1993, 5, 563-570.
4. Karam JH. Pancreatic hormones and diabetes mellitus.hypoglycemic disorders In: Basic & Clinical Endocrinology, Greenspan FS, Strewler GJ eds, Appleton & Lange, 1997, pp 595-679.
5. Kruszynska YT, Home PD, Hanning I, Alberti KGMM. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia, 1987, 30, 16-21.
6. Zavaroni I, Deferrari G, Bonora E, et al. A. Renal metabolism of C-peptide in man. J Clin Endocrinol Metab, 1987, 65, 494-498.
7. Galloway JA, Hooper SA, Spradlin CT, et al. Biosynthetic human proinsulin. Diabetes Care, 1992, 15, 666-692.
8. Regeur L, Faber OK, Binder C.Plasma C-peptide in uraemic patients. Scand J Clin Lab Invest, 1978, 38, 771-775.
9. Faber OK, Kehlet H, Sten Madsbad, Binder C. Kinetics of human C-peptide in man. Diabetes, 27, Suppl 1, 207-209.
10. Ostrega D, Polonsky K, Nagi D, et al.. Measurement of proinsulin intermediates. Diabetes, 1995, 44, 437-440.
11. Reaven GM, Chen YDI, Hollenbeck CB, Sheu WHH, Ostrega D, Polonsky KS. Plasma insulin, peptide-C, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab, 1993, 76, 44-48.
12. Sobey WJ, Beer SF, Carrington CA, et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J, 1989, 260, 535-541.
13. Lang DA, Matthews DE, Burnett M, Ward GM, Turner RC. Pulsatile, synchronous basal insulin and glucagon secretion in man. Diabetes, 1982, 31, 22-26.
14. Nicolau GY, Haus E, Lakatua DJ, et al. Circadian and circannual variations in plasma immunoreactive insulin (IRI) and C-peptide concentrations in elderly subjects. Endocrinologie, 1983, 21, 243-255.
15. Balks HJ, Schmidt A, Prank K, Hemmer F, von zur Mühlen A, Brabant G. Temporal pattern of pancreatic secretion and plasma glucose levels after nutritional stimulation. J Clin Endocrinol Metab, 1992, 75, 1198-1203.
16. Stuns J, O'Meara N, Shapiro EM, et al. Differential effects of glucose stimulation upon rapid pulses and ultradian oscillations of insulin secretion. J Clin Endocrinol Metab, 1993, 76, 895-901.
17. Mejean L, Stricker-Krongrad A, Lluch A. Chronobiologie, nutrition et métabolisme. Path Biol, 1996, 44, 603-609.
18. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996, 334, 777-783.
19. Berman N, Center P, Chou H-F, Cortez C, Bowsher R, Ipp E. Erratic oscillatory characteristics of plasma insulin concentrations in patients with insulinoma: mechanism for unpredictable hypoglycemia. J Clin Endocrinol Metab, 1997, 82, 2899-2903.
20. Jarrett RJ, Baker IA, Keen H, Oakley NW. Diurnal variation in oral glucose tolerance: blood sugar and plasma insulin levels morning, afternoon, and evening. BMJ, 1972, 1, 199-201.
21. Bristow AF, Gaines Das RE, Banghan DR. World Health Organization international standards for highly purified human, porcine and bovine insulins. J Biol Sandard, 1988, 16, 165-178.
22. Trethewey J. Bio-assays for the analysis of insulin. J Pharm Biomed Anal, 1989, 7, 189-197.
23. Clark PMS, Hales CN. How to measure plasma insulin. Diabetes/ Metabolism Reviews, 1994, 10, 79-90.
24. Smith DJ, Venable RM, Collins J. Separation and quantitation of insulins and related substances in bulk insulin crystals and in injectables by reversed-phase high-performance liquid chromatography and the effect of temperature on the separation. J Chromatogr Sci, 1985, 23, 81-88.
25. Given BD, Ostrega DM, Polonsky KS, Baldwin D, Kelley RI, Rubenstein AH. Hypoglycemia due to surreptitious injection of insulin: diagnosis by high-pressure liquid chromatography. Diabetes Care, 1991, 14, 544-547.
26. Linde S, Welinder BS, Nielsen JH. Analysis of proinsulin and its conversion products by reversed-phase high-performance liquid chromatography. J Chromatogr, 1993, 614, 185-204.
27. Kippen AD, Cerini F, Vadas L, et al. Development of an isotope dilution assay for precise determination of insulin, C-peptide, and proinsulin levels in non-diabetic and type 2 diabetic individuals with comparison to immunoassay. J Biol Chem, 1997, 272, 12513-12522.
28. Storch MJ, Alexopoulos A, Kerp L Evaluation of a solid-phase monoclonal antibody-based enzyme immunoassay for insulin in human serum. J Immunol Methods, 1989, 119, 53-57.
29. Alpha B, Cox L, Crowther N, Clark PMS, Hales CN. Sensitive amplified immunoenzymometric assays (IEMA) for human insulin and intact proinsulin. Eur J Clin Chem Clin Biochem, 1992, 30, 27-32.
30. Temple R, Clark PMS, Hales CN. Measurement of insulin secretion in type 2 diabetes: problems and pitfalls. Diabetic Med, 1992, 9, 503-512.
31. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME. Enzyme immunoassay for intact insulin in serum or plasma. Clin Chem, 1993, 39, 578-582.
32. Robbins DC, Andersen L, Bowsher R, et al. Report of the American Diabetes Association's Task Force on standardization of the insulin assay. Diabetes, 1996, 45, 242-256.
33. Deberg M, Houssa P, Frank BH, Sodoyez-Goffaux F, Sodoyez J-C. Highly specific radioimmunoassay for human insulin based on immune exclusion of all insulin precursors. Clin Chem, 1998, 44, 1504-1513.
34. Temple RC, Clark PM, Nagi DK, Schneider AE, Yudkin JS, Hales CN. Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol (Oxf) 1990, 32, 689-693.
35. Authier F, Posner BI, Bergeron JJM. Insulin-degrading enzyme. Clin Invest Med, 1996, 13, 149-160.
36. Brodal BP. The influence of haemolysis on the radioimmunoassay of insulin. Scand J Clin Lab Invest, 1971, 28, 287-290.
37. O'Rahilly S, Burnett MA, Smith RF, Darley JH, Turner RC. Haemolysis affects insulin but not C-peptide immunoassay. Diabetologia, 1987, 30, 394-396.
38. Chevenne D, Letailleur A, Trivin F, Porquet D. Effect of hemolysis on the concentration of insulin in serum determined by RIA and IRMA. Clin Chem, 1998, 44, 354-356.
39. Sapin R, Ongagna JC, Gasser F, Grucker D. Insulin measurements in haemolysed serum: influence of insulinase inhibitors. Clin Chim Acta, 1998, 274, 111-117.
40. Armitage M, Wilkin T, Wood P, Casey C, Loveless R. Insulin autoantibodies and insulin assay. Diabetes, 1988, 37, 1392-1396.
41. Sapin R. Anti-insulin antibodies in insulin immunometric assays: a still possible pitfall. Eur J Clin Chem Clin Biochem, 1997, 35, 365-367.
42. Casesnoves A, Mauri M, Domingucz JR, Alfayate R, Pico AM. Influence of anti-insulin antibodies on insulin immunoassays in the autoimmune insulin syndrome. Ann Clin Biochem, 1998, 35, 768-774.
43. Davidson JK, Debra DW. Immunologic insulin resistance. Diabetes, 1978, 27, 307-318
44. Zuppinger K, Aebi C, Fankhauser S, et al. Comparison of human and porcine insulin therapies in children with newly diagnosed diabetes mellitus. Diabetologia, 1987, 30, 912-915.
45. Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care, 1989, 12, 641-648.
46. Greenbaum CJ, Palmer JP. Insulin antibodies and insulin autoantibodies. Diabetic Med. 1991, 8, 97-105.
47. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care, 1993, 16, Suppl. 3, 155-165.
48. Wilkin T, Hoskins PJ, Armitage M, et al. Value of insulin autoantibodies as serum markers for insulin-dependent diabetes mellitus. Lancet, 1985, 2, 480-481.
49. Sodoyez JC, Sodoyez-Goffaux F, Koch M, et al. Clonally restricted insulin autoantibodies in a cohort of 2200 healthy blood donors. Diabetologia, 1990, 33, 719-725.
50. Bingley PJ for the ICARUS Group. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives. Diabetes, 1996,45, 1720-1728.
51. Uchigata Y, Tokunaga K, Nepom G, et al. Differential immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Diabetes, 1995, 44, 1227-1232.
52. Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol, 1971, 33, 732-738.
53. Nakagawa S, Nakayama H, Sasaki T, et al. Simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes, 1973, 22, 590-600.
54. Kuzuya H, Blix PM, Horwitz LW, Steiner DF, Rubenstein AH. Determination of free and total insulin and peptide-C in insulin-treated diabetics. Diabetes, 1977, 26, 22-29.
55. Rudkowki R, Antony G. The effect of immediate polyethylene glycol precipitation on free insulin measurements in diabetic patients with insulin antibodies. Diabetes, 1986, 35, 253-257.
56. Arnqvist H, Olsson P-O, Von Schenck H. Free and total insulin as determined after precipitation with polyethylene glycol: analytical characteristics and effects of sample handling and storage. Clin Chem, 1987, 33, 93-96.
57. Besch W, Keilacker H, Kohnert K-D, Ziegler M. Influence of polyethylene glycol extraction on the peptide-C determination in sera from insulin-dependent diabetic patients with circulating insulin antibodies. Exp Clin Endocrinol, 1990, 95, 119-122.
58. Boscato LM, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem, 1986, 32, 1491-1495.
59. Kohse KP. Wisser H. Antibodies as a source of analytical error. J Clin Chem Clin Biochem, 1990, 28, 881-892.
60. Levinson SS. The nature of heterophilic antibodies and their role in immunoassay interference. J Clin Immunoassay, 1992, 15, 108-115.
61. Livesey JH, Hodgkinson SC, Roud HR, Donald RA. Effect of time, temperature and freezing on the stability of immunoreactive LH, FSH, TSH, growth hormone, prolactin and insulin in plasma. Clin Biochem, 1980, 13, 151-155.
62. Kubasik NP, Ricotta M, Hunter T, Sine HE. Effect of duration and temperature of storage on serum analyte stability: examination of 14 selected radioimmunoassay procedures. Clin Chem, 1982, 28, 164-165.
63. Myrick JE, Gunter EW, Magio VL, Miller DT, Hannon WH. An improved radioimmunoassay of peptide-C and its application in a multiyear study. Clin Chem, 1989, 35, 37-42.
64. Faber OK, Binder C. C-peptide: an index of insulin secretion. Diabetes Metab Rev, 1986, 2, 331-345.
65. Snorgaard O, Lassen LH, Binder C. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr. Diabetes Care, 1992, 15, 1009-1013.
66. Greco AV, Crucitti F, Ghirlanda G, et al. Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis. Diabetologia, 1979, 17, 23-28.
67. Petrides AS, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth H. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology, 1998, 28, 141-149.
68. DeFronzo RA, Tobin JD, Rowe LW, Andres R. Glucose intolerance in uremia: quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest, 1978, 62, 425-435.
69. Hartling SG, Garne S, Binder C, et al. Proinsulin, insulin, and C-peptide in cystic fibrosis after an oral glucose tolerance test. Diabetes Res, 1988, 7, 165-169.
70. Chevenne D, Ruiz J, Lohmann L., et al. Immunoradiometric assay of human intact proinsulin applied to patients with type 2 diabetes, impaired glucose tolerance, and hyperandrogenism. Clin Chem, 1994, 40, 754-757.
71. Levy JC, Clark PM, Hales CN, Turner RC. Normal proinsulin response to glucose in mild type 2 subjects with subnormal insulin response. Diabetes, 1993, 42, 162-169.
72. Davies MJ, Metcalfe J, Gray IP, Day JL, Hales CN. Insulin deficiency rather than hyperinsulinemia in newly diagnosed type 2 diabetes mellitus. Diabetic Med, 1993, 10, 305-312.
73. Yoshioka N, Kuzuya T, Matgsuda A, Taniguchi M, Iwamoto Y. Effects of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM. Diabetes, 1989, 38, 262-266.
74. Nagi DK, Ali M, Yudkin JS. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentration in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabetic Med, 1996, 13, 753-757.
75. Davies MJ, Metcalfe J, Day JL, Hales CN, Gray IP. Improved beta cell function, with reduction in secretion on intact and 32/33 split proinsulin, after dietary intervention in subjects with type 2 diabetes mellitus. Diabetic Med. 1993, 11, 71-78.
76. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes, 1997, 46, 1725-1732.
77. Davis SN, Piatti PM, Monti L, et al. Proinsulin and insulin concentrations following intravenous glucose challenges in normal, obese, and non-insulin-dependent diabetic subjects. Metabolism, 1993, 42, 30-35.
78. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM-a balanced overview. Diabetes Care, 1992, 15, 318-368.
79. Cohen RM, Given BD, Licinio-Paixao J, et al. Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia. Metabolism 1986, 35, 1137-1146.
80. Kao PC, Taylor RL, Service FJ. Proinsulin by immunochemiluminometric assay for the diagnosis of insulinoma. J Clin Endocrinol Metab, 1994, 78, 1048-1051.
81. Haffner SM, Mykkänen L, Valdez RA, et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab. 1994, 79, 1806-1810.
82. Haneda M, Polonsky KS, Bergenstal RM, et al. Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Engl J Med, 1984, 310, 1288-1294.
83. Nanjo K, Kondo M, Sanke T, Nishi M. Abnormal insulinemia. Diab Res Clin Pract, 1994, Suppl 24, S135-S141.
84. Yano H, Kitano N, Morimoto M, Polonsky KS, Imura H, Seino Y. A novel point mutation in the human insulin gene giving rise to hyperproinsulinemia (proinsulin Kyoto). J Clin Invest, 1992, 89, 1902-1907.
85. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 1979, 28, 1039-1057.
86. World Health Organization: Diabetes Mellitus: Report of a WHO study group. Geneva, WHO, 1985 (Tech. Rep. Ser., No. 727).
87. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 1997, 20, 1183-1197.
88. Alberti KGMM, Zimmet PZ for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med, 1998, 15, 539-553.
89. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism, 1984, 33, 68-75.
90. Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med, 1991, 26, 938-948.
91. Whitelaw DC, Gilbey SG. Insulin resistance. Ann Clin Biochem, 1998, 35, 567-583.
92. Bingley PJ, Colman P, Eisenbarth GF, et al. Standardization of IVGTT to predict IDDM. Diabetes Care, 1992, 26, 1313-1316.
93. Solberg HE. The theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem, 1983, 21, 749-760.
94. Solberg HE. The theory of reference values. Part 1. The concept of reference values. J Clin Chem Clin Biochem, 1987, 25, 337-342.
95. Boyns DR, Crossley JN, Abrams ME, Jarrett RJ, Keen H. Oral glucose tolerance and related factors in a normal population sample. I.Blood sugar, plasma insulin, glyceride, and cholesterol measurements and the effects of age and sex. Br Med J, 1969, 1, 595-598.
96. Bonora E, Zavaroni I, Alpi O, et al. Insulin and C-peptide responses to 75 g oral glucose load in the healthy man. Diabetes Metab, 1986, 12, 143-148.
97. Castro A, Scott JP, Grettie DP, Macfarlane D, Bailey RE. Plasma insulin and glucose responses of healthy subjects to varying glucose loads during three-hour oral glucose tolerance tests. Diabetes, 1970, 19, 842-851.
98. Reaven GM, Olefsky J, Farquhar JW. Does hyperglycaemia or hyperinsulinaemia characterise the patient with chemical diabetes? Lancet, (7763), 1972, 1247-1249.
99. Fajans SS, Floyd JC, Pek S, Conn JW. Studies on the natural history of asymptomatic diabetes in young people. Metabolism, 1973, 22, 327-336.
100. Starkman HS, Soeldner JS, Gleason RE. Oral glucose tolerance: relationship with hemoglobin Alc. Diabetes Res Clin Pract, 1987, 3, 343-349.
101. Snehalatha C, Satyavani K, Sivasankari S, Vijay V, Ramachandran A. Insulin secretion and action in different stages of glucose tolerance in Asian Indians. Diabet Med, 1999, 16, 408-414.
102. Chevenne D, Leger J, Levy-Marchal C, et al. Proinsulin and specific insulin responses to an oral glucose tolerance test in a healthy population. Diabetes Metab, 1998, 24, 260-261.
103. Mak RHK, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron, 1992, 61, 377-382.
104. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders. The Bruneck study. Diabetes, 1998, 47, 1643-1649.
105. De Fronzo R, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol, 1979, 237, E214-23.
106. Raynaud E, Brun J-F, Pérez-Martin A, Fédou C, Mercier J. Evaluation in vivo de la sensibilité à l'insuline et applications cliniques. Ann Biol Clin, 1998, 56, 407-416.
107. Bergman RN, Watanabe R, Rebrin K, Ader M, Steil G. Toward an integrated phenotype in pre-NIDDM. Diabetic Med. 1996, 13, S67-S77.
108. Olefsky J, Farquhar JW, Reaven GM. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes, 1973, 22, 507-513.
109. Hollenbeck CB, Chen N, Chen Y-D I, Reaven GM. Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes, 1984, 33, 460-464.
110. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol, 1993, 137, 959-965.
111. Philips DIW, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabetic Med, 1994, 11, 286-292.
112. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28, 412-419.
113. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensititvity in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 1998, 83, 2694-2698.
114. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio heart study. Diabetes, 1997, 20, 1087-1092.
115. Olefsky J, Reaven GM. Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes, 1974, 23, 449-453.
116. Emoto M, Nishizawa Y, Maekawa K, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care, 1999, 22, 818-822.
117. Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn study. Diabetologia, 1996, 39, 298-305.
118. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obsese Japanese subjects. Diabetes Care, 1997, 20, 1562-1568.
119. Widjaja A, Morris RJ, Levy JC, Frayn KN, Manley SE, Turner RC. Within-and between-subject variation in commonly measured anthropometric and biochemical variables. Clin Chem, 1999, 45, 561-566.
120. Kadowaki T, Miyake Y, Haguara R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia, 1984, 26, 44-49.
121. Kosaka K, Kuzuya T, Hagura R, Yoshinaga H. Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus: the usefulness of a decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus. Diabetic Med, 1996, 13, S109-S119.
122. Yoneda H, Ikegami H, Yamamoto Y, et al. Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care, 1992, 15, 1517-1521.
123. Wareham NJ, Philipps DI, Byrne CD, Hales CN. The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabetic Med, 1995, 12, 931.
124. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med, 1988, 319, 1500-1509.
125. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med, 1993, 329, 1988-1992.
126. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege E. Risk factors for NIDDM in white population. Paris prospective study. Diabetes, 1991, 40, 796-799.
127. Røder ME, Knip M, Hartling SG, Karjalainen J, Akerblom HK, Binder C, The childhood diabetes in Finland study group. Disproportionately elevated proinsulin levels precede the onset of insulin-dependent diabetes mellitus in siblings with low first phase insulin responses. J Clin Endocrinol Metab, 1994, 79, 1570-1575.
128. Srikanta S, Ganda OP, Gleason RE, Jackson RA, Soeldner JS, Eisenbarth GS. Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose. Diabetes, 1984, 33, 717-720.
129. Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia, 1991, 34, 93-102.
130. Vialettes B, Mattei-Zevaco C, Badier C, Ramahandridona G, Lassmann-Vague V, Vague Ph. Low acute insulin response to intravenous glucose. A sensitivier but non-specific marker of early stages of type 1 (insulin-dependent) diabetes. Diabetologia, 1988, 31, 592-596.
131. Robert JJ, Deschamps I, Chevenne D, Gardais E, Roger M, Boilard C. Relation of first phase insulin secretion to age, HLA, ICA status and development of type I diabetes in 220 juvenile first degree relatives of diabetic patients. Diabetes Care, 1991, 14, 718-723.
132. Leahy JL. Natural history of β-cell dysfunction in NIDDM. Diabetes Care, 1990, 13, 992-1010.
133. McCulloch DK, Koerker DJ, Kahn SE, Bonner-Weir S, Palmer JP. Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozotocin-administered baboons. Diabetes, 1991, 40, 673-679.
134. Davies MJ, Rayman G, Grenfell A, Gray IP, Hales CN. Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance. Diabetic Med, 1994, 11, 432-436.
135. Smith CP, Tarn AC, Thomas JM, et al. Between and within subject variation of the first phase insulin response to intravenous glucose. Diabetologia, 1988, 31, 123-125.
136. Rayman G, Clark P, Schneider AE, Hales CN. The first phase insulin response to intravenous glucose is highly reproducible. Diabetologia, 1990, 33, 631-634.
137. Chase HP, Voss MA, Butler-Simon N, Hoops S, O'Brien D, Dobersen MJ. Diagnosis of pre-type 1 diabetes. J Pediatrics, 1987, 111, 807-812.
138. Whipple AO. Hyperinsulinism in relation to pancreatic tumor. Surgery, 1944, 126, 289-298.
139. Service FJ. Hypoglycemia. Endocrinol Metab Clin North Am, 1997, 26, 937-955.
140. Stanley CA. Hyperinsulinism in infants and children. Ped Clin North Am, 1997, 44, 363-374.
141. de Lonlay-Debency P, Poggi-Travert F, Fournet JC, et al. Clinical features of 52 neonates with hyperinsulinism. N Engl J Med, 1999, 340, 1169-1175.
142. Marks V. The measurement of blood glucose and the definition of hypoglycemia. Horm Metab Res, 1976, Suppl 6, 1-6.
143. Cornblath M, Schwartz R, Aynsley-Green A, Loyd JK. Hypoglycemia in infancy: the need for a rational definition. Pediatrics, 1990, 85, 834-837.
144. Koh TH, Vong SK. Definition of neonatal hypoglycaemia: is there a change? J Paediatr Child Health, 1996, 32, 302-305.
145. Marks V, Teale JD. Investigation of hypoglycaemia. Clin Endocrinol, 1996, 44, 133-136.
146. Stanley CA, Baker L. Hyperinsulinism in infancy: diagnosis by demonstration of abnormal response to fasting hypoglycemia. Pediatrics, 1976, 57, 702-711.
147. Koh TH, Aynsley-Green A, Tarbit M, Eyre JA. Neural dysfunction during hypoglycaemia. Arch Dis Child, 1988, 63, 1353-1358.
148. Mitrakou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol, 1991, 260, E67-74.
149. Morris AA, Thekekara A, Wilks Z, Clayton PT, Leonard JV, Aynsley-Green A. Evaluation of fasts for investigating hypoglycaemia or suspected metabolic disease. Arch Dis Child, 1996, 75, 15-119.
150. Service FJ, O'Brien PC, McMahon M, Kao PC. C-peptide during the prolonged fast in insulinoma. J Clin Endocrinol Metab, 1993, 76, 655-659
151. V Marks. Hypoglycaemia-real and unreal, lawful and unlawful: the 1994 Banting Lecture. Diabetic Med, 1995, 12, 850-864.
152. Dozio N, Scavini M, Beretta A, et al. Imaging of the buffering effect of insulin antibodies in the autoimmune hypoglycemic syndrome. J Clin Endocrinol Metab, 1998, 83, 643-648.
153. O'Brien T, O'Brien PC, Service FJ. Insulin surrogates in insulinoma. J Clin Endocrinol Metab, 1993, 77, 448-451
154. Pildes RS, Hart RJ, Warmer R, Cornblath M. Plasma insulin response during oral glucose tolerance tests in newborns of normal and gestational diabetic mothers. Pediatrics, 1969, 44, 76-83.
155. Rosenbloom AL, Wheeler L, Bianchi R, Chin FT, Tiwari CM, Grgic A. Age-adjusted analysis of insulin responses during normal and abnormal glucose tolerance tests in children and adolescents. Diabetes, 1975, 24, 820-828.
156. Lestradet H, Deschamps I, Giron B. Insulin and free fatty acid levels during oral glucose tolerance tests and their relation to age in 70 healthy children. Diabetes, 1976, 25, 505-508.
157. Josefsberg Z, Vilunski E, Hanukuglu A, et al. Glucose and insulin responses to an oral glucose load in normal children and adolescents in Israel. Isr J Med Sci, 1976, 12, 189-194.
158. Janik JS, Track NS, Filler RM. Motilin, human pancreatic polypeptide, gastrin and insulin plasma concentration in fasted children. J Pediatrics, 1982, 101, 54-56.
159. Lautala P, Akerblom HK, Viikari J, et al. Atherosclerosis precursors in Finnish children and adolescents.VII. Serum immunoreactive insulin. Acta Pædiatrica Scand [Suppl], 1985, 318, 127-133.
160. Leibowitz G, Weintrob N, Pikarsky A, et al. Normal proinsulin processing despite beta-cell dysfunction in persistent hyperinsulinaemic hypoglycaemia of infancy (nesidioblastosis). Diabetologia, 1996, 39, 1338-1344.
161. Smith CP, Archibald HR, Thomas JM, et al. Basal and stimulated insulin levels rise with advancing puberty. Clinical Endocrinol 1988. 28, 7-14.
162. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. N Engl J Med, 1986, 315, 215-219.
163. Svec F, Nastasi K, Hilton C, Bao W, Srinivasan SR, Berenson GS. Black-white contrasts in insulin levels during pubertal development. Diabetes, 1992, 41, 313-317.
164. DeFronzo RA. Glucose intolerance and aging: evidence for tissue insensitivity to insulin. Diabetes, 1979, 28, 1095-1101.
165. Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. J Clin Invest, 1983, 71, 1523-1535.
166. Pacini G, Valerio A, Beccaro F, Nosadini R, Cobelli C, Crepaldi G. Insulin sensitivity and beta-cell responsitivity are not decreased in elderly subjects with normal OGTT. J Am Geriat Soc, 1988, 36, 317-323.
167. Chen M, Bergman RN, Porte Jr D. Insulin resistance and β-cell dysfunction in aging: the importance of dietary carbohydrate. J Clin Endocrinol Metab, 1988, 67, 951-957.
168. Wang JT, Ho LT, Tang KT, Wang LM, Chen Y-DI, Reaven GM Effect of habitual physical activity on age-related glucose intolerance. J Am Ger Soc 1989, 37, 203-209.
169. Shimizu M, Kawazu S, Tomono S, et al. Age-related alteration of pancreatic β-cell function. Diabetes Care, 1996, 19, 8-11.
170. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U. Insulin action and age. Diabetes, 1996, 45, 947-953.
171. Orchard TJ, Becker DJ, Kuller LH, Wagener DK, LaPorte RE, Drash AL. Age and sex variations in glucose tolerance and insulin reponses: parallels with cardiovascular risk. J Chron Dis, 1982, 35, 132-132.
172. Menon RK, Cohen RM, Sperling MA, Cutfield WS, Mimouni F, Khoury JC. Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus. N Engl J Med, 1990, 323, 309-315
173. Bolli GM, Dimitriadis GD, Pehling GB, et al. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. New Engl J Med, 1984, 30, 1706-1711.
174. Walker M, Berrish TS, Stewart MW, Humphriss DB, Barriocanal L, Alberti KG. Metabolic heterogeneity in impaired glucose tolerance. Metabolism, 1997, 46, 914-917.
175. Kosaka K, Kuzuya T, Yoshinaga H, Hagura R. A prospective study of health check examinees for the development of non-insulin-dependent diabetes mellitus: relationship of the incidence of diabetes with the initial insulinogcnic index and degree of obesity. Diabetic Med. 1996, 13, S120-S126.
176. O'Rahilly SP, Nugent Z, Rudenski AS, et al. Beta-cell dysfunction rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet, 1986, 2, 360-364.
177. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med, 1992, 326, 22-29.
178. Tritos NA, Mantzoros CS. Syndromes of severe insulin resistance. J Clin Endocrinol Metab, 1998, 83, 3025-3030.
179. Flier JS, Eastman RC, Minaker KL, Maltesen D, Rowe JW. Acanthosis nigricans in obese women with hyperandrogenism. Diabetes, 1985, 34, 101-107.
180. Robert JJ., Rakotoambinina B, Cochet I, et al. The development of hypcrglycacmia in patients with insulin-resistant generalyzed lipoatrophic syndromes. Diabetologia, 1993, 36, 1288-1292.
181. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl 1996, 413, 2-28.
182. D'Ercole AJ, Underwood LE, Groelke J, Plet A. Leprechaunism: studies of the relationship among hyperinsulinism, insulin resistance, and growth retardation. J Clin Endocrinol Metab, 1979, 48, 495-502.
183. Takahashi Y, Kadowaki H, Momomura K, et al. A homozygous kinase-defective mutation in the insulin receptor gene in a patient with leprechaunism. Diabetologia, 1997, 40, 412-420.
184. Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K. Long-term effect of recombinant human insulin-like growth factor 1 on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab, 1998, 83, 542-549.
185. Carrol RJ, Hammer RE, Chan SJ, Swift HH, Rubenstein AH, Steiner DF. A mutant human proinsulin is secreted from islets of Langerhans in increased amounts via an unregulated pathway. Proc Natl Acad Sci USA, 1988, 85, 8943-8947.
186. Shibasaki Y, Kawakami T, Kanazawa Y, Akanuma Y, Takaku F. Posttranslational cleavage of proinsulin is blocked by a point mutation in familial hyperproinsulinemia. J Clin Invest, 1985, 76, 378-380.
187. Barbetti F, Raben N, Kadowaki T, et al. Two unrelated patients with familial hyperproinsulinemia due to a mutation substituting histidine for arginine at position 65 in the proinsulin molecule: identification of the mutation by direct sequencing of genomic deoxyribonucleic acid amplified by polymerase chain reaction. J Clin Endocrinol Metab, 1990, 71, 164-169.
188. Oohashi H, Ohgawara H, Nanjo K, et al. Familial hyperproinsulinemia associated with NIDDM. A case study. Diabetes Care, 1993, 16, 1340-1346.
189. Nakashima N, Sakamoto N, Umeda F, et al. Point mutation in a family with hyperproinsulinemia detected by single-stranded conformational polymorphism. J Clin Endocrinol Metab, 1993, 76, 633-636.
190. Roder ME, Vissing H, Nauck MA. Hyperproinsulinemia in a three-generation Caucasian family due to mutant proinsulin (Arg65-His) not associated with impaired glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. J Clin Endocrinol Metab, 1996, 81, 1634-1640.
191. Warren-Perry MG, Manley SE, Ostrega D, et al. A novel point mutation in the insulin gene giving rise to hyperproinsulinemia. J Clin Endocrinol Metab, 1997, 82, 1629-1631.
192. O'Rahilly S, Gray H, Humphreys PJ, et al. Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med, 1995, 333, 1386-1390.
193. Shoelson S, Haneda M, Blix P, et al. Three mutant insulins in man. Nature, 1983, 302, 540-543.
194. Nanjo K, Miyano M, Kondo M, et al. Insulin Wakayama: familial mutant insulin syndrome in Japan. Diabetologia, 1987, 30, 87-92.
195. Sakura H, Iwamoto Y, Sakamoto Y, Kuzuya T, Hirata H. Structurally abnormal insulin in a diabetic patient: characterization of the mutant insulin A3(Val→Leu) isolated from the pancreas. J Clin Invest, 1986, 78, 1666-1672.
196. Record CO. Glucose and insulin metabolism in cirrhosis. Advances in cirrhosis, hyperammonemia, and hepatic encephalopathy. Felipo and Grisolia Eds, pp 229-233, Plenum Press, New York, 1997.
197. Kruszynska YT, Harry DS, Mohamed-Ali V, Home PD, Yudkin JS, McIntyre N. The contribution of proinsulin and des-31,32 proinsulin to the hyperinsulinemia of diabetic and nondiabetic cirrhotic patients. Metabolism, 1995, 44, 254-260.
198. Yoshida T, Ninomiya K, Matsumoto T, Baatar D, Bandoh T, Kitano S. Glucagon and insulin metabolism in cirrhotic patients. Hepatogastroenterology, 1998, 45, 468-471.
199. Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med, 1970, 282, 182-187.
200. Rabkin R, Unterhalter SA, Duckworth WC. Effect of prolonged uremia on insulin metabolism by isolated liver and muscle. Kidney Int, 1979, 16, 433-439.
201. Mondon CE, Dolkas CB, Reaven GM. Effect of acute uremia on insulin removal by the isolated rat liver and muscle. Metabolism, 1978, 27, 133-142.
202. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int, 1997, Suppl 62, S48-S52.
203. 3 corrects insulin and lipid abnormalities in uremia. Kidney Int, 1998, 53, 1353-1357.
204. Kautzky-Willer A, Pacini G, Barnas U, et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int, 1995, 47, 200-206.